BioTech Stocks To Watch | AMRN | MNKD | GILD | GENE | ONCY

0

BioTech Stocks NewsAmarin (NASDAQ: AMRN) Is Down In Morning Trading After Yesterday’s Gains

Amarin (NASDAQ: AMRN) has had a pretty hectic week in the market. After a big analyst upgrade, the stock skyrocketed at the end of last week before correcting in the beginning of this week. Yesterday, Amarin stocks climbed by well over 10%. As I suggested yesterday, we are seeing a bit of a correction in morning trading today; however, I still think the stock will end in the green. Currently (11:08), Amarin stocks are trading for $2.45 per share after falling 8.24% so far today.

Outlook – When it comes to Amarin, we’ve seen quite a bit of volatility in the market lately. Huge gains followed by big losses have been the story. Nonetheless, the losses haven’t taken the stock down to where it started before the gains, so we’re still seeing an uptrend. As I’ve said in the past, when a stock grows too much, too fast, we tend to see corrections. While Amarin may be going through a correction at the moment, I think this is still a very strong stock for long term growth.

MannKind (NASDAQ: MNKD) Stocks Are On The Rise Once Again

MannKind (NASDAQ: MNKD) stocks have had a rough time in the market over the past month following what I believe to be an unfounded downgrade. Nonetheless, the downgrade started a downtrend. However, today, things are a bit different. As more and more news comes out about the growing diabetes problem in the United States, it seems as though investors are getting interested in MannKind stocks once again. Currently (10:30), the stock is trading at $5.52 per share after gaining 0.91% so far today.

Outlook – MannKind is a great company that’s been dealt a bit of a bad hand recently. Nonetheless, the company is tackling a growing problem; and doing a good job of it. With that said, I think we’re going to see this one climb in the long run!

Gilead Sciences (NASDAQ: GILD) Stocks Are Back On The Uptrend

Gilead Sciences (NASDAQ: GILD) was down for two days in a row following a policy shift that could affect its bottom line. However, I think it’s important to note here that the company has made several advancements in the medical field, continues to dominate with the HCV franchise and has the ability to show tremendous growth! All of that being said, Gilead Sciences stock is back on the rise. Currently (10:29), the stock is trading at $101.39 per share after a gain of 1.11% so far today.

Outlook – Gilead Sciences is a great company with a dominate position in the space. Yesterday, I had someone tell me that all the BioTech space does is lose money. Gilead Sciences is a perfect example of why that statement is wrong! With that said, this is another great option for long term growth in my opinion.

Genetic Technologies (NASDAQ: GENE) Is Up Following Dilution Problems

Genetic Technologies (NASDAQ: GENE) stocks have been falling dramatically recently. The cause of the drop is simple. The company raised millions of dollars; issuing new shares to do so. As a result, the new shares hitting the market caused a major share dilution issue, sending the value of the stock plummeting. However, it seems as though investors are happy with where the stock is headed from here, as the value of Genetic Technologies shares are up today. Currently, Genetic Technologies is trading fro $4.06 per share after a gain of 4.10% so far today.

Outlook – As I’ve mentioned in previous posts, I like Genetic Technologies for the long run. Sure, dilution can be a major drain on value, but in this case it may be opening opportunities for investors to get a cheap entrance into the growth.

Oncolytics (NASDAQ: ONCY) Stocks Climb Even After An Analyst Downgrade

Today, news became available that Needham & Company lowered Oncolytics (NASDAQ: ONCY) target price to $1.50, insinuating upward growth at a slower than originally expected rate. Nonetheless, the stock price doesn’t seem to be reacting negatively to the change. Currently (10:40), Oncolytics is trading for $0.81 per share after gaining 3.85% so far today.

Outlook – Oncolytics is a great company that seems primed for long term growth!

What Are Your Thoughts?

Do you have an opinion on any of the stocks mentioned here? We’d love to read it in the comments below!

Image Credit

LEAVE A REPLY

Please enter your comment!
Please enter your name here